Form 10-K for the fiscal year ended December 31, 2025
Regarding the disclosure on page 6 about collaborating with multiple institutions globally and your investigator-sponsored trials program across several disease areas, please tell us and revise your future filings, beginning with your March 31, 2026 Form 10-Q, to specifically address the collaborations entered into with GSK and Revolution Medicines and provide the significant related terms of each, including anyRest of the question
consideration exchanged thus far. We note these collaborations were entered into prior to the filing of your Form 10-K and are highlighted in your fourth quarter of 2025 earnings release, earnings call and accompanying slides/presentation. Management’s Discussion and Analysis of Financial Condition and Results of Operations, page Results of Operations, page 73 Your research and development (R&D) expenses increased more then 220% during 2025 and also made up half of your $1.08 billion net loss for the year ended December 31, 2. 2025 and 75% of your $221.3 million net loss for the year ended December 31, 2024. For 2025, oncology clinical trial related costs made up half of your R&D expenses, yet the explanation provided for the 164% increase in these costs during the year appears limited, i.e., you attribute the large change primarily to new clinical trials added and current clinical trials expanded. Given: i) the significance of oncology clinical trial related costs to consolidated R&D and, in turn, the significance of consolidated R&D to your results of operations; ii) the multiple clinical trials which you are currently conducting; and iii) the multiple indications for which you are currently evaluating ivonescimab, please tell us whether your oncology clinical trial related costs can be further disaggregated by indication, trial or some other level and revise future filings as applicable.
In response to the Staff’s request, theRead in the reply
Company respectfully acknowledges the Staff’s comment and advises the Staff that there has not been any cash consideration exchanged in connection with our collaborations with GSK and Revolution Medicines to date. These are agreements to engage in one or more clinical trials combining ivonescimab with a third-party drug, where Summit is providing ivonescimab for the trial. The third party is acting as the study sponsor and is responsible for the associated costs of the studies beyond the cost of ivonescimab.Rest of the answer
For these reasons, these collaborations do not include any upfront payments, milestone payments, or royalty sharing provisions.
In future filings, beginning with our Form 10-Q for the quarter ended March 31, 2026, the Company will provide additional disclosure related to the collaborations with GSK and Revolution Medicines and the significant related terms of each collaboration, including whether any cash consideration has been exchanged. The following disclosure will be included in our Form 10-Q for the quarter ended March 31, 2026:
In June 2025, the Company entered into a clinical trial collaboration with Revolution Medicines, Inc.
(“RevMed”) to evaluate ivonescimab in combination with three RevMed RAS(ON) inhibitors (the “RevMed Collaboration”). In January 2026, the Company entered into a clinical trial collaboration with GSK plc to evaluate ivonescimab in combination with GSK’s novel B7-H3, risvutatug rezetecan, in multiple solid tumors (the “GSK Collaboration”). Neither the RevMed Collaboration nor the GSK Collaboration include upfront payments, milestone payments, or royalty sharing provisions. For the quarter ended March 31, 2026, there was no cash consideration exchanged in connection with either the RevMed Collaboration or the GSK Collaboration.
First report after the company's reply of Apr 16, 2026: 10-Q filed Apr 30, 2026 ↗, against the 10-Q filed Oct 20, 2025 ↗.
The part of the filing the question names could not be found in both reports. Read them on sec.gov.
Also in this review: closing letter, 2026-04-27